For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Background Biomarker changes that occur in the period between normal cognition and the
diagnosis of sporadic Alzheimer's disease have not been extensively investigated in …

Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

The brain has almost no energy reserve, but its activity coordinates organismal function, a
burden that requires precise coupling between neurotransmission and energy metabolism …

Glutamate is the primary excitatory neurotransmitter of the brain. Cellular homeostasis of
glutamate is of paramount importance for normal brain function and relies on an intricate …

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases,
characterized by impaired cognitive function due to progressive loss of neurons in the brain …

Astrocytes contribute to the complex cellular pathology of Alzheimer's disease (AD).
Neurons and astrocytes function in close collaboration through neurotransmitter recycling …